Whalesbook
Biocon Results: Profit Dump Hua, Share Kaise Bhaaga?
Dekho, abhi poora India Q4 results ke maze le raha hai aur Biocon ne bhi apne numbers nikal diye hain. Agar sirf profit dekho toh asliyat mein ₹345 Crore se ghata hokar ₹126 Crore ho gaya hai is quarter mein. Reason? Pichhle saal lenalidomide sales se bahut zyada profit tha aur is baar ek 'exceptional item' bhi aa gaya. Matlab, numbers thode gadbad lag rahe hain.
Lekin bhai, numbers ke alawa bhi kuch dekha jata hai market mein. Revenue thoda sa, 2.3% growth ke saath ₹4,517 Crore tak pahunch gaya. Aur jo company ka core business hai, biosimilars, woh toh 12% tak badh gaya hai. Stock May 8, 2026 ko ₹380-₹390 ke levels pe around 2% se zyada upar trade kar raha tha. Iska matlab market profit drop ko ignore kar raha hai aur kuch aur hi dekh raha hai.
Biocon Biologics Integration: Game Changer?
Sabse bada reason stock ke bhagne ka ye ho sakta hai ki Biocon Biologics ka integration almost done hai. Isko March 31, 2026 tak poora finalize karne ka target hai. Isse company ka structure simple ho jayega, balance sheet mazboot hogi aur jo 'holding company discount' pehle lagta tha Viatris acquisition ke baad, woh khatam ho jayega. Management abhi operating utilization badhane aur margins ko improve karne par full focus kar rahi hai, jo market mein bahut zaroori hai.
Valuation Aur Risk Factor
Ek cheez jo sabko notice karni chahiye, woh hai Biocon ka valuation. Agar competitors jaise Dr. Reddy's, Cipla ko dekho toh unka P/E ratio 17-24 ke beech hai, aur Sun Pharma ka 32-40 ke aas paas. Lekin Biocon ka P/E ratio 72.13 se lekar 7615 tak dikh raha hai! Ye bahut high hai, matlab market expecting bahut hai. Agar ye log profit growth nahi dikha paye, toh stock mein girawat bhi tez ho sakti hai. US generics market mein bhi pressure hai aur Revlimid jaise drugs ke patent expiry ka bhi asar pad sakta hai.
Aur haan, leadership change bhi hone wala hai. Kiran Mazumdar-Shaw apni niece, Claire Mazumdar ko leadership hand over karne wali hain. Ye sab cheezein thodi caution wali hain, investors ko dhyan dena padega.
Analysts Kya Kehte Hain?
Chunautiyon ke bawajood, analysts abhi bhi Biocon par bullish hain. Kaafi log 'Moderate Buy' bol rahe hain aur average target price ₹435 ke aas paas de rahe hain, matlab abhi bhi 21% tak ka upside potential dikh raha hai. Investors ab naye leadership aur US mein Humira biosimilar ke performance par nazar rakhenge.